STAT Bulletin

January 10, 2017 Volume: 15 Issue: 1

To: All MD/DO

Contracts affected: All lines of business

(unless indicated)

Drug Therapy Guideline Updates Available Online

Why you're
receiving this
stat

We want you to know that the latest drug therapy guideline updates are now available.

What you need to know

The attached drug therapy guidelines have been reviewed and updated by our Pharmacy and Therapeutics Committee.

This update is a result of the guideline review and new drug evaluations performed quarterly by our Pharmacy and Therapeutics Committee.

What you need to do

These guidelines are currently available online at **bsneny.com**. To access them, select *Policies & Guidelines > Drug Therapy Guidelines*.

Reminder: FEP drug formularies are updated quarterly and are available at caremark.com/wps/portal.

Please refer to these updated guidelines when discussing treatment options with your BlueShield patients.

If you do not have access to the Internet, you may request a paper copy by calling Provider Service at 1-800-444-4552 or (518) 220-5620.

Drug Therapy Guidelines Updates Please refer to individual policies for details.

New Guidelines

Epaned®

Exondys 51™

Lartruvo™

Zinplava™

Updated Guidelines

Abbreviated Criteria- Syprine®
Actemra®
Cimzia [®]
Cinqair [®]
Cosentyx®
Enbrel®
Erectile Dysfunction Agents
Esbriet®
Ferriprox®
Forteo®
Grastek®
Humira [®]
Infliximab (formerly titled Remicade)®
Immune Globulins
Intravenous (IV) Bisphosphonates
Kalydeco®
Kineret®
Krystexxa®
Nucala®
Nutritional Supplements/Enteral Formulas

Ofev®
Oralair®
Orencia (IV and SC)®
Orkambi®
Otezla®
Preferred Drug Step Therapy: BPH (alpha antagonists)
Preferred Drug Step Therapy: Beta Agonist Inhalers
Preferred Drug Step Therapy: Inhaled Combinations
Preferred Drug Step Therapy: Inhaled Corticosteroids
Preferred Drug Step Therapy: Intranasal Steroids
Preferred Drug Step Therapy: Osteoporosis Agents
Preferred Drug Step Therapy: Urinary Agents
Procysbi®
Promacta®
Pulmonary Arterial Hypertension (PAH) Agents
Ragwitek®
RANKL Inhibitors

Simponi [®]
Stelara [®]
Taltz®
Tykerb®
Uloric®
Valchlor®
Vectibix®
Vidaza®
Votrient®
Xalkori [®]
Xeljanz [®]
Xolair [®]
Xtandi [®]
Yervoy®
Zaltrap®
Zelboraf®
Zolinza®
Zurampic [®]
Zydelig [®]
Zykadia™
Zytiga [®]

Deleted Guidelines

Benign Prostatic Hyperplasia (BPH) Agents Dermatologic Agents

Reminder: FEP drug formularies are updated quarterly and are available at caremark.com/wps/portal.